menu
    • menu

    Company profile for AnnJi Pharmaceutical

    NEW Drugs in Dev: 3
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 2014, AnnJi Pharmaceutical Co., Ltd. (AnnJi) is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy’s disease, or SBMA (Spinal and bulbar muscular atrophy).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AnnJi PharmaceuticalTaiwan Flag
    Country
    Country
    Taiwan
    Address
    Address
    B405, No. 18, Siyuan St., Zhongzheng Dist., Taipei City 100
    Telephone
    Telephone
    +886 2 2365-5677
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ajpharm.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grants Fast Track Designation for AJ201 for Kenndy's Disease
    FDA Grants Fast Track Designation for AJ201 for Kenndy's Disease

    23 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-for-aj201-a-first-in-class-therapy-for-kenndys-disease-302592312.html

    PR NEWSWIRE
    23 Oct 2025
    Share Share
    Annji Showcases Clinical Breakthrough Of AJ201 At WMS 2025
    Annji Showcases Clinical Breakthrough Of AJ201 At WMS 2025

    13 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/annji-showcases-clinical-breakthrough-of-aj201-at-wms-2025-302581832.html

    PR NEWSWIRE
    13 Oct 2025
    Share Share
    AnnJi Pharma Reports Positive Phase 1/2a results for AJ20
    AnnJi Pharma Reports Positive Phase 1/2a results for AJ20

    21 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/annji-pharmaceutical-company-announces-positive-phase-12a-results-for-aj201-in-spinal-and-bulbar-muscular-atrophy-sbma-patients-302462634.html

    PR NEWSWIRE
    21 May 2025
    Share Share
    AnnJi Pharma inks deal worth $250 M for muscular atrophy treatment
    AnnJi Pharma inks deal worth $250 M for muscular atrophy treatment

    14 Mar 2023

    // BIOSPECTRUM ASIA

    https://www.biospectrumasia.com/news/26/22097/taiwan-based-startup-annji-pharma-inks-deal-worth-250-m-for-muscular-atrophy-treatment.html

    BIOSPECTRUM ASIA
    14 Mar 2023
    Share Share
    AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics
    AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics

    10 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/annji-pharmaceutical-announced-a-licensing-agreement-with-avenue-therapeutics-to-develop-and-commercialize-aj201-a-first-in-class-clinical-asset-for-the-treatment-of-kennedys-disease-301768817.html

    PR NEWSWIRE
    10 Mar 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search